While the new COVID-19 strain continues to raise concerns, A Velumani, CMD & CEO of Thyrocare, said that they are not seeing spike in testing due to the new strain.
“I do not see any surge in December compared to November. We had the highest workload in the month of September when it was peaking and subsequently various segments of verticals have stopped or reduced testing. So, October was lesser, November was much lesser, and even December is lower. I do not see in the last 10 days any spurt because of the fear of the new strain,” he said on CNBC-TV18.
On COVID-19 test prices, Velumani said that though some states have cut test rates to Rs 500, Thyrocare is still making some profit due to volumes.
“There are some states who went down as low as even Rs 500, which is impossible – I think laboratories there have been closed down. We still make some profits because we have volumes and the price cutting has reduced small players to give up, medium players subsequently are giving up. It looks like only large players can operate because at this rate it is impossible to operate without volumes,” he said.
On non-COVID testing, he said, “Right from August onwards based upon the percentage of lockdown removed, every month we found 5-10 percent increase in the non-COVID test. In the month of December, month-over-month we are 10 percent higher. So I have a reason to believe that when the year ends, March 2021, we should be 20-25 percent high in the non-COVID segment and there is a likelihood that COVID may not figure in the balancesheet significantly.”